An observational study in Non Small Cell Lung Cancer, sponsored by Fox Chase Cancer Center. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Fox Chase Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Carcinoma, Non-Small-Cell Lung by Fox Chase Cancer Center — 2 open to participants now, 4 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Fox Chase Cancer Center.
Among the 22 studies in Carcinoma, Non-Small-Cell Lung by Fox Chase Cancer Center, this one is the only one that started in 2026, is the only observational one, and was the 22nd registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 22 studies in Carcinoma, Non-Small-Cell Lung by Fox Chase Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 1 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 36 across the 19 interventional studies, 200 across the 1 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fox Chase Cancer Center is the lead sponsor of 216 studies on the registry; 29 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
2 of the studies in Carcinoma, Non-Small-Cell Lung by Fox Chase Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03786692Fox Chase Cancer CenterPhase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | 2026-12 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Carcinoma, Non-Small-Cell Lung by Fox Chase Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study will evaluate whether a blood test can detect the return of non-small cell lung cancer at least three months before it is identified on routine imaging. The test measures circulating tumor DNA (ctDNA), which consists of small pieces of DNA released by cancer cells into the blood. Detecting ctDNA after treatment may indicate that cancer cells remain in the body, even when cancer is not visible on scans.
Approximately 200 adults with stage IB-IIIA non-small cell lung cancer who are considered candidates for surgery will participate at Fox Chase Cancer Center. Participants will receive standard-of-care treatment selected by their treating physicians, which may include chemotherapy and immunotherapy before or after surgery. Blood samples will be collected before treatment and at scheduled times during treatment and follow-up. Researchers will compare ctDNA results with routine imaging and clinical outcomes to assess how well the test predicts cancer recurrence.
Participants will be followed for up to five years after surgery, with the primary analysis focused on the first three years. Additional research in a subset of participants will examine blood, tissue, and stool samples to explore relationships among immune responses, gut bacteria, treatment response, and cancer recurrence.
This prospective, single-center observational cohort study will evaluate the clinical validity of a blood-based circulating tumor DNA (ctDNA) assay for detecting molecular residual disease (MRD) and predicting recurrence in patients with surgically resectable stage IB-IIIA non-small cell lung cancer (NSCLC), as defined by the American Joint Committee on Cancer (AJCC) 9th edition. Approximately 200 treatment-naïve adults who are considered surgical candidates by their treating physicians will be enrolled at Fox Chase Cancer Center over approximately two years.
Participants will receive standard-of-care treatment according to multidisciplinary tumor board recommendations and the treating physician's clinical judgment. Treatment pathways may include surgery followed by adjuvant therapy, neoadjuvant chemoimmunotherapy followed by surgery and adjuvant therapy, or neoadjuvant therapy followed by surgery and observation. The protocol does not assign anticancer treatment or specify the selection of therapeutic agents.
Tumor tissue and peripheral blood will be collected for MRD assessment. Tumor tissue will preferably be obtained before neoadjuvant treatment; surgical tissue may be used when a pretreatment specimen is unavailable or when participants proceed directly to surgery. Blood samples for ctDNA analysis will be collected at baseline and at protocol-specified treatment time points. A postoperative blood sample obtained four to six weeks after surgery will establish the landmark MRD assessment. Additional samples will be collected during and after adjuvant treatment, as applicable. During surveillance, MRD blood samples will be collected every three months for the first three years and every six months thereafter, for up to five years.
Clinical disease assessments will use standard-of-care computed tomography (CT) scans, radiology reports, and the treating physician's clinical assessment. Participants will be followed for up to five years after surgery or until radiographically confirmed disease progression, subject to protocol discontinuation criteria. Participants who initiate neoadjuvant therapy but do not undergo surgery will remain in follow-up, with blood collection continuing when feasible. Their available data will contribute to exploratory analyses, but they will not be evaluable for analyses requiring surgical pathology or the postoperative landmark assessment.
The primary objective is to determine the proportion of evaluable participants with documented recurrence in whom ctDNA predicts recurrence at least three months before clinical confirmation. The primary analysis will evaluate recurrence within 36 months after surgery. Secondary objectives include assessing the association between postoperative landmark ctDNA status and recurrence-free survival; determining the proportion of participants with negative ctDNA results at treatment entry; evaluating the sensitivity, specificity, positive predictive value, and negative predictive value of landmark ctDNA results for three-year recurrence; and measuring the interval between the first positive ctDNA result and clinically confirmed recurrence. Recurrence-free survival is defined as the time from the four-to-six-week postoperative ctDNA measurement to the first documented recurrence or death from any cause.
Exploratory analyses will examine longitudinal ctDNA patterns and associations with treatment pathways, clinicopathologic characteristics, genomic alterations, and recurrence. In the first 50 participants receiving neoadjuvant therapy, additional blood, surgical tumor or tumor-bed tissue, lymph node tissue, and stool samples will support correlative studies. These studies will evaluate immune cell profiles, T-cell clonotype dynamics, and gut microbiome characteristics in relation to pathologic response, MRD status, and disease recurrence.
Adults aged 18 years or older with treatment-naïve, histologically or cytologically confirmed stage IB-IIIA non-small cell lung cancer (AJCC 9th edition) who are considered candidates for surgical resection by their treating physicians. Approximately 200 participants will be enrolled at Fox Chase Cancer Center. Participants will receive standard-of-care treatment, which may include neoadjuvant therapy, surgery, and adjuvant therapy, as clinically indicated. Enrollment includes surgical candidates regardless of whether neoadjuvant therapy is planned.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must be willing and able to provide a core tumor .
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with treatment-naïve, histologically or cytologically confirmed stage IB-IIIA non-small cell lung cancer (AJCC 9th edition) who are considered surgical candidates by their treating physicians. Participants receive standard-of-care treatment, which may include neoadjuvant therapy, surgery, and adjuvant therapy, as clinically indicated. Serial blood samples and tumor tissue are collected for circulating tumor DNA and molecular residual disease analyses, with follow-up for cancer recurrence for up to five years after surgery. The first 50 participants receiving neoadjuvant therapy undergo additional blood, tissue, and stool collection for correlative studies.
Proportion of Participants With ctDNA Detection at Least Three Months Before Clinically Confirmed Recurrence
Proportion of evaluable participants with documented lung cancer recurrence within 36 months after surgery who have a positive circulating tumor DNA (ctDNA) result at least three months before clinically confirmed recurrence. Recurrence is determined using standard-of-care imaging. The primary analysis includes participants with at least three months of follow-up and at least one evaluable ctDNA result obtained at or after the four-to-six-week postoperative assessment.
Time frame: Up to 36 months after surgery.
Recurrence-Free Survival by Postoperative ctDNA Status
Recurrence-free survival is measured from the ctDNA assessment performed four to six weeks after surgery to the first documented recurrence or death from any cause, whichever occurs first. Outcomes will be compared between participants with positive and negative ctDNA results at this postoperative landmark. Participants without an event will be censored at their last disease assessment.
Time frame: From the four-to-six-week postoperative ctDNA assessment through up to five years after surgery.
Proportion of Participants With Negative ctDNA Results at Treatment Entry
Proportion of participants with a negative ctDNA result at entry into treatment. Treatment entry is defined as Cycle 1, Day 1 of neoadjuvant therapy for participants receiving neoadjuvant treatment, or the date of surgery for participants proceeding directly to surgical resection.
Time frame: At treatment entry: Cycle 1, Day 1 of neoadjuvant therapy or the date of surgery.
Sensitivity of Postoperative ctDNA for Predicting Three-Year Recurrence
Proportion of participants who experience clinically confirmed recurrence within three years after surgery who have a positive ctDNA result at the four-to-six-week postoperative landmark assessment. The estimate will be reported with a 95% confidence interval.
Time frame: ctDNA assessed four to six weeks after surgery; recurrence assessed through 36 months after surgery.
Specificity of Postoperative ctDNA for Predicting Three-Year Recurrence
Proportion of participants who do not experience clinically confirmed recurrence within three years after surgery who have a negative ctDNA result at the four-to-six-week postoperative landmark assessment. The estimate will be reported with a 95% confidence interval.
Time frame: ctDNA assessed four to six weeks after surgery; recurrence assessed through 36 months after surgery.
Positive Predictive Value of Postoperative ctDNA for Three-Year Recurrence
Proportion of participants with a positive ctDNA result at the four-to-six-week postoperative landmark assessment who experience clinically confirmed recurrence within three years after surgery. The estimate will be reported with a 95% confidence interval.
Time frame: ctDNA assessed four to six weeks after surgery; recurrence assessed through 36 months after surgery.
Negative Predictive Value of Postoperative ctDNA for Three-Year Recurrence
Proportion of participants with a negative ctDNA result at the four-to-six-week postoperative landmark assessment who do not experience clinically confirmed recurrence within three years after surgery. The estimate will be reported with a 95% confidence interval.
Time frame: ctDNA assessed four to six weeks after surgery; recurrence assessed through 36 months after surgery.
Time From First Positive ctDNA Result to Clinically Confirmed Recurrence
Time interval, measured in months, between the first positive ctDNA result and clinically confirmed recurrence among participants with both events. The interval will be summarized using descriptive statistics. The number and proportion of participants with positive ctDNA results without subsequent recurrence, and those with recurrence without a positive ctDNA result, will also be reported.
Time frame: Through up to five years after surgery.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2029, 35 months later.
Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 35 months is below that.
Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →